Ramius Capital Discloses 5.2% Stake in Alsius (ALUS)
More News related to ALUS
- ALSIUS (ALUS) Misses Q3 EPS by 2c
- Alsius (ALUS) Announces FDA Clearance to Market Solex(TM) Heat Exchange Catheter
- Ramius Capital Discloses 5.2% Stake in Alsius (ALUS)
More News related to 13Gs
- RW Baird Makes Positive Comments on Incyte (INCY) Following Novartis Deal
- Incyte (INCY) Strikes Major Drug Development Deal with Noavartis
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Incyte (INCY) In License Agreement With Novartis, Worth Up to $1 Billion
- Gen-Probe (GPRO) Gets U.S. FDA Clearance for Marketing Prodesse's ProParaflu+ Assay
In a 13G filing on Alsius (Nasdaq: ALUS), Ramius Capital disclosed a 5.2% stake (995,580 shares) in the company. A 13G indicates a "passive investment."
A the quarter ended Sept 30, 2007, Ramius held a warrant position in Alsius. The company recently announced the early exercise of warrants.
Alsius is a commercial-stage medical device company that develops, manufactures and sells proprietary products to precisely control patient temperature in hospital critical care settings.
Ramius Capital is a $10 billion hedge fund founded in 1994 by Peter Cohen (former Chairman and CEO of Shearson Lehman Brothers) with Jeffrey Solomon (former CAO and Head of Corporate Development at Republic New York Securities Corp.).
Related Categories
13GsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
